Format

Send to

Choose Destination
See comment in PubMed Commons below
Sex Transm Dis. 2009 Aug;36(8):515-21. doi: 10.1097/OLQ.0b013e3181a74c2c.

Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom.

Author information

1
Hull York Medical School, University of York, Department of GU Medicine, York HIV Research Group, York YO31 7WA, UK. sarah.woodhall@hyms.ac.uk

Abstract

BACKGROUND:

Data on the burden of genital warts in terms of treatment costs and detriment to quality of life (QoL) are required to assess cost-effectiveness of quadrivalent human papillomavirus vaccination. We investigated the cost of treatment and period of time for which QoL is affected to obtain estimates of quality-adjusted life year (QALY) loss associated with an episode of genital warts.

METHODS:

Adults diagnosed with genital warts attending the York sexually transmitted disease clinic during two 3-month periods in 2006 and 2007 were enrolled (n = 189). Data on cost of treatment and duration of episode of care were collected from a retrospective case note review. QALY loss was calculated by applying estimates of the duration of time for which QoL was affected to the previously reported detriment to QoL associated with genital warts.

RESULTS:

The average cost per episode of care was 286 US dollars (139 pound, 95% CI: 246-327 US dollars). Estimated loss of QALYs ranged from 0.0045 (95% CI: 0.0014-0.0078) to 0.023 (95% CI: 0.0072-0.039).

CONCLUSIONS:

Genital warts present a significant burden both to individuals and to the health service. Data on the burden of genital warts should be incorporated into economic evaluations of human papillomavirus vaccination strategies.

PMID:
19543143
DOI:
10.1097/OLQ.0b013e3181a74c2c
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center